6942-39-8

Basic information

• Product Name: METHYL 2-BROMO-5-FLUOROBENZOATE
• Synonyms: METHYL 2-BROMO-5-FLUOROBENZOATE;RARECHEM AL BF 0749;Methyl 2-bromo-5-fluorobenzoate 98%;Methyl2-bromo-5-fluorobenzoate98%;1-Bromo-4-fluoro-2-(methoxycarbonyl)benzene;Benzoic acid, 2-broMo-5-fluoro-, Methyl ester;Methyl 6-bromo-3-fluorobenzoate;NSC 57466
• CAS NO: 6942-39-8
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.03
• Product Categories: blocks;Bromides;Carboxes;FluoroCompounds;Benzene series;Acids & Esters;Bromine Compounds;Fluorine Compounds
• Mol File: 6942-39-8.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 247.5 °C at 760 mmHg
• Flash Point: 103.5 °C
• Appearance: /
• Density: 1.577 g/cm³
• Vapor Pressure: 0.0255mmHg at 25°C
• Refractive Index: 1.5350 to 1.5390
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 2-BROMO-5-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-BROMO-5-FLUOROBENZOATE(6942-39-8)
• EPA Substance Registry System: METHYL 2-BROMO-5-FLUOROBENZOATE(6942-39-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 6942-39-8(Hazardous Substances Data)

Usage

General Description

Methyl 2-Bromo-5-Fluorobenzoate is a synthetic, organic chemical compound with the molecular formula C8H6BrFO2. It is characterized by a bromine, fluorine and methyl ester group attached to a benzene ring which contributes to its reactivity in chemical synthesis. METHYL 2-BROMO-5-FLUOROBENZOATE is commonly used as an intermediate in organic chemistry, facilitating the synthesis of other chemical compounds, primarily in the pharmaceutical industry. It appears as a crystalline solid and should be handled with caution due to its potential for causing skin and eye irritation. As of now, there's limited information available about its environmental impact and potential health hazards.

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)6-4-5(10)2-3-7(6)9/h2-4H,1H3

Upstream product

• 394-28-5 2-Bromo-5-fluorobenzoic acid 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 1914-40-5 4-Chlor-7-fluor-2-nitro-9-oxo-fluoren 
• 606080-43-7 methyl 2-cyano-5-fluorobenzoate 
• 1021539-49-0 methyl 5-fluoro-2-{[(4aS,5R)-1-(4-fluorophenyl)-5-hydroxy-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl]ethynyl}benzoate 
• 1256593-15-3 (E)-methyl 2-(2-cyanovinyl)-5-fluorobenzoate 
• 1426309-20-7 2-[5-fluoro-3-(2-fluorobenzyl)-1H-indazol-1-yl]-4-iodo-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426307-93-8 2-[5-fluoro-3-(2-fluorobenzyl)-1H-indazol-1-yl]-4-hydroxy-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426309-18-3 2-[1-(2-bromo-5-fluorophenyl)-2-(2-fluorophenyl)ethylidene]hydrazinecarboximidamide 
• 1426309-19-4 5-fluoro-3-(2-fluorobenzyl)-1H-indazole-1-carboximidamide 
• 1228787-13-0 4-amino-2-[5-fluoro-3-(2-fluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 

Relevant articles and documents

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

The YAP-TEAD transcriptional complex is responsible for the expression of genes that regulate cancer cell growth and proliferation. Dysregulation of the Hippo pathway due to overexpression of TEAD has been reported in a wide range of cancers. Inhibition of TEAD represses the expression of associated genes, demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization experiments confirmed that LM98 is anchored within the palmitic acid pocket of TEAD. LM98 reduces the expression of CTGF and Cyr61, inhibits MDA-MB-231 breast cancer cell migration and arrests cell cycling in the S phase during cell division.

INHIBITORS OF THE MENIN-MLL INTERACTION

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects

The synthesis and pharmaceutical activity of new potent non-tetrazole angiotensin II (Ang II) receptor antagonists were described. These compounds were fluorine substituted derivatives of Losartan, Valsartan and Irbesartan with carboxylic acid group as re